BIOMAT Database Logo BIOMAT Database Logo

[The pharmacokinetic and biopharmaceutical evaluation of the new tranquilizer gidazepam]. 1993

G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova

The pharmacokinetics of the new tranquilizer gidazepam and its desalkyl metabolite was studied in rats. Some biopharmaceutical characteristics of the agents under study were defined. Gidazepam was found to have much advantage over the principal active ingredient (desalkylgidazepam) in its higher bioavailability. The methodological approaches developed by the authors to evaluate the efficacy of gidazepam may be applied in designing novel drugs.

UI MeSH Term Description Entries
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002627 Chemistry, Physical The study of CHEMICAL PHENOMENA and processes in terms of the underlying PHYSICAL PHENOMENA and processes. Physical Chemistry,Chemistries, Physical,Physical Chemistries
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D001570 Benzodiazepinones
D001702 Biopharmaceutics The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action. Pharmaceutics,Pharmaceutic
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D014151 Anti-Anxiety Agents Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. Anti-Anxiety Agent,Anti-Anxiety Drug,Anxiolytic,Anxiolytic Agent,Anxiolytic Agents,Tranquilizing Agents, Minor,Anti-Anxiety Drugs,Anti-Anxiety Effect,Anti-Anxiety Effects,Antianxiety Effect,Antianxiety Effects,Anxiolytic Effect,Anxiolytic Effects,Anxiolytics,Tranquillizing Agents, Minor,Agent, Anti-Anxiety,Agent, Anxiolytic,Agents, Anti-Anxiety,Agents, Anxiolytic,Agents, Minor Tranquilizing,Agents, Minor Tranquillizing,Anti Anxiety Agent,Anti Anxiety Agents,Anti Anxiety Drug,Anti Anxiety Drugs,Anti Anxiety Effect,Anti Anxiety Effects,Drug, Anti-Anxiety,Drugs, Anti-Anxiety,Effect, Anti-Anxiety,Effect, Antianxiety,Effect, Anxiolytic,Effects, Anti-Anxiety,Effects, Antianxiety,Effects, Anxiolytic,Minor Tranquilizing Agents,Minor Tranquillizing Agents
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
[The new Soviet tranquilizer--gidazepam].
September 1991, Fel'dsher i akusherka,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
[Pharmacokinetic evaluation of the tablet dosage forms of gidazepam prepared by various technologies].
January 2004, Eksperimental'naia i klinicheskaia farmakologiia,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
[The pharmacokinetic aspects of the clinical action of gidazepam].
January 1993, Eksperimental'naia i klinicheskaia farmakologiia,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
Biopharmaceutical evaluation of cyanidanol tablets using pharmacokinetic techniques.
January 1973, Arzneimittel-Forschung,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
[Effect of the tranquilizer gidazepam on the behavioral reactions of rats in the first weeks after resuscitation].
January 1994, Patologicheskaia fiziologiia i eksperimental'naia terapiia,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
Reflections on the critical evaluation of a new tranquilizer.
December 1958, American practitioner and digest of treatment,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
Evaluation of a new minor tranquilizer: tybamate (Solacen).
December 1965, JAMA,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
[An experimental study of the pharmacokinetic mechanisms for the development of gidazepam tolerance].
January 1993, Eksperimental'naia i klinicheskaia farmakologiia,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
Biopharmaceutical and clinical pharmacokinetic profile of bromazepam.
February 1976, Journal of pharmacokinetics and biopharmaceutics,
G B Kolyvanov, and A A Kruchenkov, and A A Litvin, and V P Zherdev, and S G Otabekova
Clinical evaluation of a new phenothiazine tranquilizer, fluphenazine (prolixin).
November 1959, The American journal of psychiatry,
Copied contents to your clipboard!